NanoViricides, Inc. (NASDAQ:NNVC)

PRESS RELEASE

published on 05/11/2026 at 14:30, 3 months 3 days ago

Recent Hantavirus On A Cruise Ship Highlights the Need for Broad-Spectrum Antiviral Drugs Such as NV-387, Says NanoViricides
NanoViricides, Inc. highlights the need for a revolutionary antiviral drug like NV-387 as response to Andes hantavirus incident on a cruise ship, emphasizing potential global epidemic risk

NV-387 NanoViricides Inc. Antiviral Drug Andes Hantavirus Global Epidemic
BRIEF

published on 05/04/2026 at 14:35, 3 months 10 days ago

Le NV-387 de NanoViricides obtient la désignation de médicament orphelin pour le traitement de la rougeole

NanoViricides NV-387 Désignation De Médicament Orphelin FDA Américaine Traitement De La Rougeole
BRIEF

published on 05/04/2026 at 14:35, 3 months 10 days ago

NanoViricides' NV-387 Receives Orphan Drug Designation for Measles Treatment

NanoViricides NV-387 Orphan Drug Designation Measles Treatment US FDA
PRESS RELEASE

published on 05/04/2026 at 14:30, 3 months 10 days ago

NV-387 for The Treatment of Measles is Granted Orphan Drug Designation by The US FDA
NanoViricides, Inc. receives US FDA Orphan Drug Designation for antiviral drug NV-387, targeting Measles treatment. The drug shows strong efficacy in in vivo studies

NanoViricides NV-387 Orphan Drug Designation Antiviral Drug Measles Treatment
BRIEF

published on 04/21/2026 at 14:35, 3 months 23 days ago

Le NV-387 s'impose comme une solution essentielle dans la lutte contre les épidémies de rougeole

Santé Mondiale Vaccination Épidémie De Rougeole Traitement NV-387 Maladies Pédiatriques
BRIEF

published on 04/21/2026 at 14:35, 3 months 23 days ago

NV-387 Emerges as a Critical Solution in Combating Measles Outbreaks

Global Health Vaccination Measles Outbreak NV-387 Treatment Pediatric Disease
PRESS RELEASE

published on 04/21/2026 at 14:30, 3 months 23 days ago

Deadly Measles Cases Accentuate the Need for a Treatment - NV-387 is Here to Help Patients and Control Spread, Says NanoViricides
NanoViricides, Inc. comments on their drug candidate NV-387 as a weapon against measles outbreaks worldwide. The drug shows promise in treating patients and preventing transmission

NV-387 NanoViricides Inc. Drug Candidate Antiviral Treatment Measles Outbreaks
BRIEF

published on 04/07/2026 at 14:35, 4 months 7 days ago

NanoViricides Files Application for Rare Pediatric Disease Drug Designation for NV-387

NanoViricides NV-387 FDA Approval Measles Treatment Rare Pediatric Disease Drug
BRIEF

published on 04/07/2026 at 14:35, 4 months 7 days ago

NanoViricides dépose une demande de désignation de médicament pour une maladie pédiatrique rare pour le NV-387

NanoViricides NV-387 Approbation De La FDA Traitement De La Rougeole Médicament Pour Maladies Pédiatriques Rares
PRESS RELEASE

published on 04/07/2026 at 14:30, 4 months 7 days ago

Measles Rare Pediatric Disease Drug Designation Application Filed for NV-387, PRV Provides for Strong Business Case, Says NanoViricides
NanoViricides files RPDD application for NV-387 as Measles treatment with US FDA, potentially eligible for PRV upon approval. Addressing rising Measles cases, vaccination challenges

FDA NanoViricides Measles RPDD PRV

Published on 08/15/2026 at 00:50, 3 hours 12 minutes ago

Revive Therapeutics Reports Grant of Options
Published on 08/15/2026 at 00:15, 3 hours 47 minutes ago

Full Circle Lithium Announces Closing of Private Placement
Published on 08/14/2026 at 23:45, 4 hours 17 minutes ago

AI/ML Innovations Inc. Announces Proposed Private Placement
Published on 08/14/2026 at 23:25, 4 hours 37 minutes ago

NuRAN Wireless Closes $7.6 Million Financing
Published on 08/14/2026 at 23:00, 5 hours 2 minutes ago

Medicure Reports Financial Results for Quarter Ended June 30, 2026 and Schedules August 17, 2026 Conference Call

View all ACCESSWIRE

Published on 08/14/2026 at 18:29, 9 hours 33 minutes ago

Designated Persons Notifications
Published on 08/14/2026 at 18:29, 9 hours 33 minutes ago

Designated Persons Notifications
Published on 08/14/2026 at 18:15, 9 hours 47 minutes ago

Fuller, Smith & Turner PLC: Transaction in own shares
Published on 08/14/2026 at 16:05, 11 hours 57 minutes ago

GATORADE WELCOMES AITANA BONMATÍ TO TEAM GATORADE AHEAD OF THE NEW FOOTBALL SEASON
Published on 08/14/2026 at 15:29, 12 hours 33 minutes ago

Tradegate AG publishes its half-year report

View all EQS

Published on 08/13/2026 at 18:00, 1 day 10 hours ago

Chiffre d’affaires du 1er trimestre 2026-27 : 14,4 M€
Published on 08/11/2026 at 17:45, 3 days 10 hours ago

DAMARTEX / Droits de vote bruts et réels au 31 juillet 2026
Published on 08/11/2026 at 17:40, 3 days 10 hours ago

Infotel : Déclaration des transactions sur actions propres réalisées du 3 au 7 août 2026 dans le cadre du programme de rachat d’actions
Published on 08/10/2026 at 18:00, 4 days 10 hours ago

AXA: Information relating to the number of voting rights and shares making up the share capital on 31/07/2026
Published on 08/10/2026 at 18:00, 4 days 10 hours ago

AXA : Information relative au nombre total de droits de vote et d'actions composant le capital social au 31/07/2026

View all LES ECHOS COMFI WIRE

News